Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

11 The pre-specified subgroup analysis of the UNIRAD trial focused on the ET backbone as it appeared to be the only stratification factor with a strong trend towards an association with DFS, suggesting that patients treated with tamoxifen may derive a benefit from the addition of everolimus (hazard ratio 0.62, 95% CI 0.37-1.06, P = 0.044). 11 To further elucidate this intriguing finding, in this report we examine the interaction of ET and allocation to everolimus with age and menopausal status.

also in 3,373 other papers

The results are of borderline significance, and the present post hoc exploratory analyses are intended only to generate hypotheses that may help to understand the potential role of everolimus in patients with high-risk HR-positive HER2-negative early breast cancer.

also in 1,681 other papers

This subsequent post hoc analysis showed a trend in favor of everolimus in the subgroup of premenopausal patients treated with tamoxifen.

also in 33,481 other papers